JP2023525757A5 - - Google Patents

Info

Publication number
JP2023525757A5
JP2023525757A5 JP2022567882A JP2022567882A JP2023525757A5 JP 2023525757 A5 JP2023525757 A5 JP 2023525757A5 JP 2022567882 A JP2022567882 A JP 2022567882A JP 2022567882 A JP2022567882 A JP 2022567882A JP 2023525757 A5 JP2023525757 A5 JP 2023525757A5
Authority
JP
Japan
Prior art keywords
disease
independently
alkyl
case
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525757A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031381 external-priority patent/WO2021226517A1/en
Publication of JP2023525757A publication Critical patent/JP2023525757A/ja
Publication of JP2023525757A5 publication Critical patent/JP2023525757A5/ja
Pending legal-status Critical Current

Links

JP2022567882A 2020-05-08 2021-05-07 Akt3モジュレーター Pending JP2023525757A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022111P 2020-05-08 2020-05-08
US63/022,111 2020-05-08
US202063120984P 2020-12-03 2020-12-03
US63/120,984 2020-12-03
PCT/US2021/031381 WO2021226517A1 (en) 2020-05-08 2021-05-07 Akt3 modulators

Publications (2)

Publication Number Publication Date
JP2023525757A JP2023525757A (ja) 2023-06-19
JP2023525757A5 true JP2023525757A5 (cg-RX-API-DMAC10.html) 2024-05-16

Family

ID=78468495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567882A Pending JP2023525757A (ja) 2020-05-08 2021-05-07 Akt3モジュレーター

Country Status (12)

Country Link
US (1) US20230295114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4146666A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023525757A (cg-RX-API-DMAC10.html)
KR (1) KR20230022456A (cg-RX-API-DMAC10.html)
CN (1) CN115996939A (cg-RX-API-DMAC10.html)
AU (1) AU2021268210A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022022342A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182673A1 (cg-RX-API-DMAC10.html)
IL (1) IL297598A (cg-RX-API-DMAC10.html)
MX (1) MX2022014020A (cg-RX-API-DMAC10.html)
PH (1) PH12022553031A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021226517A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia
WO2021226477A1 (en) * 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators
IL312439A (en) * 2021-11-05 2024-06-01 Georgiamune Inc Akt3 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
EP2078008A2 (en) * 2006-10-12 2009-07-15 SuperGen, Inc. Quinoline derivatives for modulating dna methylation
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
JP5746015B2 (ja) * 2008-04-16 2015-07-08 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー Axlキナーゼ阻害剤としてのキノリン誘導体
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
FR2972535B1 (fr) * 2011-03-07 2014-05-02 Crime Scene Technology Trousse de revelation comprenant une tetrazine et un cyanoacrylate, procede de co-fumigation d'une tetrazine et d'un cyanoacrylate
CN102775389B (zh) * 2012-04-05 2014-12-17 华侨大学 N-取代-4-(7-氯喹啉-4-氨基)-苯甲酰胺衍生物的制备方法和应用
CN102659628B (zh) * 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
EP2875014B1 (en) * 2012-07-17 2017-11-29 Washington University Anti-mucus drugs and uses therefor
WO2017039318A1 (en) * 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
US10342868B2 (en) * 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
US10519113B2 (en) * 2016-08-17 2019-12-31 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
CN106749071B (zh) * 2017-01-10 2019-03-01 江西师范大学 一种芳香类1,2,4,5-四嗪化合物的制备方法
EP3678666B1 (en) * 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
US20210213014A1 (en) * 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
BR112022022327A2 (pt) * 2020-05-08 2023-01-03 Georgiamune Llc Moduladores de akt3 e métodos de uso dos mesmos
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2,4-二取代嘧啶衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2023524596A5 (cg-RX-API-DMAC10.html)
JP2023524600A5 (cg-RX-API-DMAC10.html)
JP6898327B2 (ja) 新規化合物
AU2018358157B2 (en) Modulators of the integrated stress pathway
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
CZ297907B6 (cs) Aminothiazolové deriváty a farmaceutické kompozice s jejich obsahem
JP2024541995A5 (cg-RX-API-DMAC10.html)
AU2018360850A1 (en) Modulators of the integrated stress pathway
CA3080808A1 (en) Modulators of the integrated stress pathway
CZ20022014A3 (cs) Aminothiazolové inhibitory na cyklin-dependentních kinas
JP2024540107A5 (cg-RX-API-DMAC10.html)
JP2017520571A5 (cg-RX-API-DMAC10.html)
JP2014510774A5 (cg-RX-API-DMAC10.html)
RU2011108024A (ru) 3-азабицикло(3.1.0) гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
MX2009001036A (es) Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
JP2014506892A5 (cg-RX-API-DMAC10.html)
JP2017532360A5 (cg-RX-API-DMAC10.html)
JP2021535112A5 (cg-RX-API-DMAC10.html)
CY1111316T1 (el) Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης
JP2023525756A5 (cg-RX-API-DMAC10.html)
RU2010140613A (ru) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
US20190202826A1 (en) Phosphotidylinositol 3-Kinase Inhibitors
JP2024541994A5 (cg-RX-API-DMAC10.html)
JP2024541975A5 (cg-RX-API-DMAC10.html)
JP2023525757A (ja) Akt3モジュレーター